750 P. R o b s o n
Brenneissen R, Egli A, Elsohly MA, Henn V, Spiess Y (1996) The effect of orally and rectally
administered delta-9-THC on spasticity: a pilot study with two patients. Int J Clin
Pharmacol Ther 34:446–452
Bridges D, Ahmad K, Rice, AS (2001) The synthetic cannabinoid WIN55,212–2 attenuates
hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133:586–
594
Brotchie JM (2000) The neural mechanisms underlying levodopa-induced dyskinesia. Ann
Neurol 47:105–114S
Budney AJ, Moore BA, Vandrey RG, et al (2003) The time course and significance of cannabis
withdrawal. J Abnorm Psychol 112:393–402
Buggy DJ, Toogood L, Maric S, et al (2003) Lack of analgesic efficacy of oral delta-9-tetra-
hydrocannabinol in postoperative pain. Pain 106:169–172
Campbell FA, Tramer MR, Carroll D, et al (2001) Are cannabinoids an effective and safe
option in the management of pain? A qualitative systematic review. Br Med J 323:13–16
Carmichael J (1992) The principles of cancer chemotherapy. In: Grahame-Smith DG, Aron-
son JK (eds) Oxford textbook of clinical pharmacology, 2nd edn. Oxford University
Press, Oxford, 505–515
Chan HSL, Correia JA, MacLeod SM (1987) Nabilone versus prochlorperazine for control
of cancer chemotherapy-induced emesis in children: a double-blind crossover trial.
Pediatrics 79:946–952
Chang AE, Shiling DJ, Stillman RC, et al (1979) Delta-9-THC as an antiemetic in cancer
patients receiving high-dose methotrexate. Ann Intern Med 91:819–830
Chaperon F, Thiebot MH (1999) Behavioural effects of cannabinoid agents in animals. Crit
Rev Neurobiol 13:243–281
Cichewicz DL, McCarthy EA (2003) Antinociceptive synergy between delta-9-tetrahydro-
cannabinol and opioids after oral administration. J Pharmacol Exp Ther 304:1010–1015
Cichewicz DL, Welch SP (2003) Modulation of oral morphine antinociceptive tolerance and
naloxone-precipitated withdrawal signs by oral delta 9-tetrahydrocannabinol. J Phar-
macol Exp Ther 305:812–817
Cichewicz DL, Rubo A, Welch SP (2003) Recovery of morphine- and codeine-induced
antinociception by delta-9-tetrahydrocannabinol. Int Cannabinoid Res Soc 13th Annu
Symp Cannabinoids, Abstr 40
Clifford DB (1983) THC for tremor in multiple sclerosis. Ann Neurol 13:669–671
ConsroeP,SniderSR(1986)Therapeuticpotentialofcannabinoidsinneurologicaldisorders.
In:MechoulamE(ed)Cannabinoidsastherapeuticagents.CRCPress,BocaRaton,21–49
Consroe P, Sandyk R, Snider SR (1986) Open label evaluation of cannabidiol in dystonic
movement disorders. Int J NeuroSci 30:277–282C
Consroe P, Laguna J, Allender J, et al (1991) Controlled clinical trial of cannabidiol in
Huntington’s disease. Pharmacol Biochem Behav 40:701–708C
Consroe P, Musty R, Rein J, Tillery W, Pertwee RG (1997) The Perceived effects of smoked
cannabis on patients with multiple sclerosis. Eur Neurol 38:44–48
Consroe PF, Wood GC, Buchsbaum H (1975) Anticonvulsant nature of marihuana smoking.
J Am Med Assoc 234:306–307
Cunha JM, Carlini EA, Pereira AE, et al (1980) Chronic administration of cannabidiol to
healthy volunteers and epileptic patients. Pharmacology 21:175–185
Dahl V, Raeder JC (2000) Non-opioid postoperative analgesia. Acta Anaesthesiol Scand
44:1191–1203
Dalzell AM, Bartlett H, Lilleyman JS (1986) Nabilone: an alternative antiemetic for cancer
chemotherapy. Arch Dis Child 61:502–505
Degenhardt L, Hall W (2002) Cannabis and psychosis. Curr Psychiatry Rep 4:191–196
Dunn M, Davis R (1974) The perceived effects of marijuana on spinal cord injured males.
Paraplegia 12:175
Einhorn LH, Nagy C, Furnas B, et al (1981) Nabilone: an effective antiemetic in patients
receiving cancer chemotherapy. J Clin Pharmacol 21:64S–69S